title: Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.
abstract: BACKGROUND
  Under the auspices of the College of American Pathologists, a multidisciplinary group of clinicians, pathologists, and statisticians considered prognostic and predictive factors in prostate cancer and stratified them into categories reflecting the strength of published evidence and taking into account the expert opinions of the Prostate Working Group members.
  
  
  METHODS
  Factors were ranked according to the previous College of American Pathologists categorical rankings: category I, factors proven to be of prognostic importance and useful in clinical patient management; category II, factors that have been extensively studied biologically and clinically but whose importance remains to be validated in statistically robust studies; and category III, all other factors not sufficiently studied to demonstrate their prognostic value. Factors in categories I and II were considered with respect to variations in methods of analysis, interpretation of findings, reporting of data, and statistical evaluation. For each factor, detailed recommendations for improvement were made. Recommendations were based on the following aims: (1) increasing uniformity and completeness of pathologic evaluation of tumor specimens, (2) enhancing the quality of data collected pertaining to existing prognostic factors, and (3) improving patient care.
  
  
  CONCLUSIONS
  Factors ranked in category I included preoperative serum prostate-specific antigen level, TNM stage grouping, histologic grade as Gleason score, and surgical margin status. Category II factors included tumor volume, histologic type, and DNA ploidy. Factors in category III included perineural invasion, neuroendocrine differentiation, microvessel density, nuclear roundness, chromatin texture, other karyometric factors, proliferation markers, prostate-specific antigen derivatives, and other factors (oncogenes, tumor suppressor genes, apoptosis genes, etc).
authors.affiliation: Bostwick Laboratories, Richmond, VA, USA.
authors.forename: D G
authors.initials: DG
authors.lastname: Bostwick
authors.forename: D J
authors.initials: DJ
authors.lastname: Grignon
authors.forename: M E
authors.initials: ME
authors.lastname: Hammond
authors.forename: M B
authors.initials: MB
authors.lastname: Amin
authors.forename: M
authors.initials: M
authors.lastname: Cohen
authors.forename: D
authors.initials: D
authors.lastname: Crawford
authors.forename: M
authors.initials: M
authors.lastname: Gospadarowicz
authors.forename: R S
authors.initials: RS
authors.lastname: Kaplan
authors.forename: D S
authors.initials: DS
authors.lastname: Miller
authors.forename: R
authors.initials: R
authors.lastname: Montironi
authors.forename: T F
authors.initials: TF
authors.lastname: Pajak
authors.forename: A
authors.initials: A
authors.lastname: Pollack
authors.forename: J R
authors.initials: JR
authors.lastname: Srigley
authors.forename: J W
authors.initials: JW
authors.lastname: Yarbro
mesh_terms: D014408:Biomarkers, Tumor; D002467:Cell Nucleus / Q000473:pathology; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D010338:Pathology, Clinical; D011003:Ploidies; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D012955:Societies, Medical; D014481:United States
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D017430:Prostate-Specific Antigen